Pilot study of a cognitive-behavioral group intervention to prevent further weight gain in Hispanic individuals with schizophrenia

Journal of the American Psychiatric Nurses Association

Volumn 13, Issue 6, 2008, Pages 353-359

  Weber, Mary ^a   Colon, Marco ^b   Nelson, Monica ^a  

^a UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^b Program of Metrocare Services   (United States)

Author keywords

Cognitive behavioral group intervention; Diabetes; Obesity; Schizophrenia

Indexed keywords

EID: 58149343077     PISSN: 10783903     EISSN: 15325725     Source Type: Journal    
DOI: 10.1177/1078390307309517     Document Type: Article

References (34)

1. Allison, D., & Casey, D. (2001). Antipsychotic-induced weight gain: A review of the literature. Journal ofClinical Psychiatry, 62 (suppl. 7), 22-31.
2. Allison, D., Fontaine, K., Heo, M., Mentore, J., Cappelleri, J., Chandler, L., et al.(1999). The distribution of body mass index among individuals with and without schizophrenia. Journal of Clinical Psychiatry, 60, 215-220.
3. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., et al.(1999). Antipsychotic induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry, 156, 1686-1696.
4. Ayllon, T. (1963). Intensive treatment of psychotic behaviour by stimulus satiation and food reinforcement. Behaviour Research and Therapy, 1 (1), 53-61.
5. Bandura, A. (1977). Self-efficacy: Toward a unifying theory of behavioral change. Psychological Review, 84, 191-215.
6. Bandura, A. (1997). Self-efficacy: The exercise of control. New York: W. H. Freeman and Company.
7. Brown, S., Birtwistle, J., Roe, L., & Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29 (3), 697-701.
8. Casey, D., Haupt, D., Newcomer, J., Henderson, D., Sernyak, M.J., Davidson, M., et al.(2004). Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. Journal ofClinical Psychiatry, 65 (suppl. 7), 4-18.
9. Centorrino, F., Wurtman, J., Duca, K., Fellman, V., Fogarty, K., Berry, J., et al.(2006). Weight loss in overweight patients maintained on atypical antipsychotic agents. International Journal of Obesity, 30, 1011-1016.
10. Cooper, Z., & Fairburn, C. (2001). A new cognitive behavioural approach to the treatment of obesity. Behaviour Research and Therapy, 39, 499-511.
11. Faulkner, G., Cohn, T., & Remington, G. (2007). Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews, Issue 1, Art. No.: CD005148.
12. Ford, E.S., Giles, W.H., & Dietz, W.H. (2002). Prevalence of the metabolic syndrome among US adults. Journal of theAmerican Medical Association, 287 (3), 356-359.
13. Green, A.I., Patel, J.K., Goisman, R.M., Allison, D.B., & Blackburn, G. (2000). Weight gain from novel antipsychotic drugs: Need for action. General Hospital Psychiatry, 22 (4), 224-235.
14. Henderson, D.C. (2002). Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Current Diabetes Reports, 2 (2), 135-140.
15. Henderson, D.C., Cagliero, E., Copeland, P.M., Borba, C.P., Evins, E., Hayden, D., et al.(2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequent sampled intravenous glucose tolerance test and minimal model analysis. Archives of General Psychiatry, 62, 19-28.
16. Henderson, D., Nguyen, D., Copeland, P., Hayden, D., Borba, C., Louie, P., et al.(2005). Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: Results of a 10-year naturalistic study. Journal of Clinical Psychiatry, 66, 1116-1121.
17. Kato, M.M., Currier, M.B., Gomez, C.M., Hall, L., & Gonzalez-Blanco, M. (2004). Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. The Primary Care Companion to the Journal ofClinical Psychiatry, 6 (2), 74-77.
18. Knowler, W.C., Barrett-Connor, E., Fowler, S.E., Hamman, R.F., Lachin, J.M., Walker, E.A., et al.(2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine, 346 (6), 393-403.
19. Lean, M., & Pajonk, F. (2003). Patients on atypical antipsychotics: Another high-risk group for diabetes. Diabetes Care, 26, 1597-1605.
20. Lieberman, J.A. (2004). Metabolic changes associated with antipsychotic use. Primary Care Companion, Journal ofClinical Psychiatry, 6 (suppl. 2), 8-13.
21. Lindenmayer, J., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J.P., et al.(2003). Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. American Journal of Psychiatry, 160 (2), 290-296.
22. Nawaz, H., & Katz, D. (2001). American College of Preventive Medicine Practice Policy Statement: Weight management counseling of overweight adults. American Journal of Preventive Medicine, 21, 73-78.
23. Newcomber, J.W. (2004). Metabolic risk during antipsychotic treatment. Clinical Therapeutics, 26 (12), 1936-1946.
24. Newcomber, J. (2006). Medical risk in patients with bipolar disorder and schizophrenia. Journal of Clinical Psychiatry, 67, e16.
25. Schwartz, T.L., Nihalani, N., Virk, S., Jindal, S., & Chilton, M. (2004). Psychiatric medication-induced obesity: Treatment options. Obesity Reviews, 5 (4), 233-238.
26. Shah, M., Coyle, Y., Kavanaugh, A., Adams-Huet, B., & Lipsky, P.E. (2000). Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematous. Arthritis Care and Research, 13 (4), 205-212.
27. Smith, S.C., Clark, L.T., Cooper, R.S., Daniels, S.R., Kumanyika, S.K., Ofili, E., et al.(2005). Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: Report of the obesity, metabolic syndrome, and hypertension writing group. Circulation, 111(10), 134-139.
28. Thakore, J.H., Mann, J.N., Vlahos, I., Martin, A., & Reznek, R. (2002). Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. International Journal of Obesity, 26 (1), 137-141.
29. Toalson, P., Ahmed, S., Hardy, T., & Kabinoff, G. (2004). The metabolic syndrome in patients with severe mental illnesses. The Primary Care Companion to the Journal ofClinical Psychiatry, 6 (4), 152-158.
30. Umbricht, D., Flury, H., & Bridler, R. (2001). Cognitive behavior therapy for weight gain [Letter to the Editor]. American Journal of Psychiatry, 158, 971.
31. Wadden, T.A., Berkowitz, R.I., Sarwer, D.B., Prus-Wisniewski, R., & Steinberg, C. (2001). Benefits of lifestyle modification in the pharmacological treatment of obesity. Archives of Internal Medicine, 161 (2), 218-227.
32. Weber, M., & Wyne, K. (2006). A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. Schizophrenia Research, 83, 95-101.
33. Williamson, D.A., & Perrin, L.A. (1996). Behavioral therapy for obesity. Endocrinology and Metabolism Clinics of North America, 25 (4), 943-954.
34. Wing, R., & Gillis, B. (1996). The diabetes prevention program's lifestyle change program. Section 7: Guidelines for implementing the DPP lifestyle intervention. Pittsburgh, PA: University of Pittsburgh. Retrieved August 13, 2007, from http://www.bsc.gwu.edu/dpp/manuals.htmlvdoc.